Bacteria cocktail aims to boost cancer immunotherapy
Disease control
Completed
This study tested a combination of an oral bacterial product (VE800) and the immunotherapy drug nivolumab in 56 people with advanced or metastatic cancers like melanoma, stomach, and colorectal cancer. The goal was to see if the bacteria could help the immune system fight tumors …
Phase: PHASE1, PHASE2 • Sponsor: Vedanta Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC